NCCN Guidelines® Insights - Survivorship, Version 1.2023 |
1.00 |
08/10/2023 - 12:00am to 08/10/2024 - 12:00am |
Recorded Presentation from the NCCN Pharmacy Updates: Ampullary Adenocarcinoma: Overview of Subtypes and Treatments |
1.00 |
09/21/2023 - 12:00am to 09/13/2024 - 12:00am |
Advances in the Management of Metastatic Castration-Resistant Prostate Cancer: Expert Guidance and Resources for the Interdisciplinary Team |
1.25 |
12/21/2023 - 12:00am to 12/21/2024 - 12:00am |
What Drives Reimbursement for Biomarker Testing? |
1.25 |
06/15/2023 - 12:00am to 06/15/2024 - 12:00am |
Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates |
1.25 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
Locoregional Management of Breast Cancer with SABCS Updates |
1.25 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
The Evolving Landscape in CLL/SLL: Best Practice Clinical Applications of Current Evidence and New Guideline Recommendations |
1.75 |
07/21/2023 - 12:00am to 07/21/2024 - 12:00am |
Advances in Hepatocellular and Biliary Tract Cancers Impacting Patient Outcomes |
1.75 |
07/21/2023 - 12:00am to 07/21/2024 - 12:00am |
Clinical Considerations in Renal Cell Carcinoma: Current Evidence, Guideline Recommendations, and a View to the Future |
1.75 |
07/21/2023 - 12:00am to 07/21/2024 - 12:00am |
Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors |
1.75 |
08/09/2023 - 12:00am to 08/09/2024 - 12:00am |
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
2.00 |
12/21/2023 - 12:00am to 12/21/2024 - 12:00am |